212 reports of this reaction
3.2% of all CALCIUM POLYCARBOPHIL reports
#2 most reported adverse reaction
DIARRHOEA is the #2 most commonly reported adverse reaction for CALCIUM POLYCARBOPHIL, manufactured by Aurobindo Pharma Limited. There are 212 FDA adverse event reports linking CALCIUM POLYCARBOPHIL to DIARRHOEA. This represents approximately 3.2% of all 6,699 adverse event reports for this drug.
Patients taking CALCIUM POLYCARBOPHIL who experience diarrhoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIARRHOEA is moderately reported among CALCIUM POLYCARBOPHIL users, representing a notable but not dominant share of adverse events.
In addition to diarrhoea, the following adverse reactions have been reported for CALCIUM POLYCARBOPHIL:
The following drugs have also been linked to diarrhoea in FDA adverse event reports:
DIARRHOEA has been reported as an adverse event in 212 FDA reports for CALCIUM POLYCARBOPHIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIARRHOEA accounts for approximately 3.2% of all adverse event reports for CALCIUM POLYCARBOPHIL, making it one of the most commonly reported side effect.
If you experience diarrhoea while taking CALCIUM POLYCARBOPHIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.